Blis Technologies lifts guidance

Blis Technologies lifts guidance
Staff reporters
Oral probiotics company Blis Technologies expects to exceed previous guidance based on further “significant growth” in product sales during March.Latest guidance for the year to end March 2020 is for earnings before interest, tax, depreciation and amortisation of about $2.1 million from revenues of $10.6 million, from prior guidance of between $1.5 million and $1.7 million and $10 million respectively.Blis Technologies chief executive Brian Watson said the company had continued to see “unprecedented demand for our Blis probiotic products throug...